Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.68 |
| ▸ | CCKAR | P32238 | 2/20 | 0.55 |
| ▸ | CCKBR | P32239 | 2/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | BRS3 | P32247 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564909 | 0.93 | OPRM1 (0.63) | OPRD1OPRM1 | |
| SCHEMBL30051966 | 0.93 | OPRM1 (0.65) | OPRD1OPRM1LTA4HBRS3 | |
| SCHEMBL30169323 | 0.91 | OPRM1 (0.62) | OPRD1OPRM1 | |
| SCHEMBL30502988 | 0.91 | OPRM1 (0.64) | OPRD1OPRM1LTA4H | |
| SCHEMBL29564479 | 0.91 | OPRD1 (0.61) | OPRD1OPRM1CCKARCCKBRLTA4H | |
| SCHEMBL30052858 | 0.90 | OPRM1 (0.69) | OPRD1OPRM1LTA4H | |
| SCHEMBL29658156 | 0.90 | OPRD1 (0.57) | OPRD1OPRM1CCKARCCKBRLTA4H | |
| SCHEMBL30051166 | 0.89 | OPRM1 (0.64) | OPRD1OPRM1BRS3 | |
| SCHEMBL31038379 | 0.89 | OPRM1 (0.66) | OPRD1OPRM1LTA4H | |
| SCHEMBL30502977 | 0.89 | OPRD1 (0.69) | OPRD1OPRM1CCKARCCKBRLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000700-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2026-01-01 | — | — | US | disclosed |
| US-20260000771-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2026-01-01 | — | — | US | disclosed |
| EP-4615509-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TargImmune Therapeutics AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| US-20250135014-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2025-05-01 | — | — | US | disclosed |
| EP-4426358-A2 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TargImmune Therapeutics AG (CH) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024100040-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2023079142-A2 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250135014-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | DCLRE1A, LIG3, LARS1 | OPRD1 3203/4885OPRM1 4059/4885CCKAR 4442/4885 |
| US-20260000771-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | PSMA1, PSMA3, PSMA2 | OPRD1 243/4885OPRM1 87/4885CCKAR 1399/4885 |
| US-20260000700-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | CTDSP1, POLM, MCTS1 | OPRD1 408/4885OPRM1 276/4885CCKAR 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.